Skip to content
Massive Bio

Massive Bio Facebook ad: “HER2-Mutant NSCLC Trials”

Massive Bio Facebook ad: HER2-Mutant NSCLC Trials

Ran for 54 days, from August 13 to October 6, 2026, the last day Crush saw it.

Run by Massive Bio on Facebook. Crush is not the advertiser and does not verify its claims. See this ad in Meta's Ad Library(opens in a new tab)

Make your own version of this ad

Crush makes it, launches it in your own Meta ad account, scales the winners and pauses the losers.

About this ad

Meta Ad Library ID
2197162194165192
Platforms
Facebook, Instagram, Audience Network, Messenger and Threads
Relaunches
0

How we count

Ad text

Patients with HER2-mutant, treatment-naïve non-squamous NSCLC may qualify for a first-line clinical trial. Identify and refer eligible cases.

massivebio.com

HER2-Mutant NSCLC Trials

HER2 mutation | Stage III–IV | No prior systemic therapy

Learn more: massivebio.com(opens in a new tab)

More from Massive Bio

See all Massive Bio ads

More ads from the top 1,000

See the top 1,000 ads